Therapeutic effects of the oriental herbal medicine Sho-saiko-to on liver cirrhosis and carcinoma

Hepatology Research

Volumn 41, Issue 9, 2011, Pages 825-837

  Lee, Jun Kyoung ^a   Kim, Jung Hoon ^a   Shin, Hyeun Kyoo ^a  

^a Korea Institute of Oriental Medicine (KIOM)   (South Korea)

Author keywords

Hepatic fibrosis; Hepatocarcinoma; Herbal medicine; Interstitial pneumonia; Liver cirrhosis; Sho saiko to

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; ANTIBIOTIC AGENT; ANTIOXIDANT; ANTIPYRETIC AGENT; ASPARTATE AMINOTRANSFERASE; COLLAGEN TYPE 1; COLLAGEN TYPE 3; DAISAIKOTO; DANAZOL; FAT DROPLET; GAMMA GLUTAMYLTRANSFERASE; GLUTATHIONE; GLYCOPROTEIN; GOKO TO; HANGE KOBOKUTO; HERBACEOUS AGENT; INTERLEUKIN 1; INTERLEUKIN 4; INTERLEUKIN 6; MAKYOKANSEKI TO; NILVADIPINE; OUREN GEDOKU TO; PREDNISOLONE; PROTEOGLYCAN; SHO SEIRYU TO; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; UNINDEXED DRUG; XIAO CHAI HU TANG; YOIN SEIHAI TO;

ACUTE RESPIRATORY FAILURE; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALCOHOL LIVER DISEASE; ANTINEOPLASTIC ACTIVITY; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIARY CIRRHOSIS; BLEEDING; CANCER CELL; CANCER CELL CULTURE; CARCINOGENESIS; CELL ACTIVATION; CELL PROLIFERATION; CHRONIC LIVER DISEASE; CLINICAL TRIAL (TOPIC); COUGHING; DIARRHEA; DISEASE COURSE; DOWN REGULATION; DYSPNEA; EXTRACELLULAR MATRIX; FATIGUE; FEVER; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HERBAL MEDICINE; HUMAN; HYPOXEMIA; IMMUNOMODULATION; INTERSTITIAL PNEUMONIA; LEUKOCYTOSIS; LIPID PEROXIDATION; LIVER CELL CARCINOMA; LIVER CELL DAMAGE; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER INJURY; LIVER NECROSIS; LIVER PROTECTION; LIVER REGENERATION; LIVER RESECTION; LIVER TOXICITY; NATURAL KILLER CELL; NONHUMAN; PATHOGENESIS; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; PROTHROMBIN TIME; PURPURA; REVIEW; SIDE EFFECT; TREATMENT DURATION; URINE COLOR; VIRUS HEPATITIS; WEAKNESS;

EID: 80052232988     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2011.00829.x     Document Type: Review

References (106)

1. Amagaya S, Umeda M, Ogihara Y. Inhibitory action of shosaikoto and daisaikoto (traditional Chinese medicine) on collagen-induced platelet aggregation and prostaglandin biosynthesis. Planta Med 1986; 5: 345-9.
2. Sakaguchi S, Tsutsumi E, Yokota K. Preventive effects of a traditional Chinese medicine (sho-saiko-to) against oxygen toxicity and membrane damage during endotoxemia. Biol Pharm Bull 1993; 16: 782-6.
3. Fujiwara K, Mochida S, Nagoshi S etal. Regulation of hepatic macrophage function by oral administration of xiao-chai-hu-tang (sho-saiko-to, TJ-9) in rats. J Ethnopharmacol 1995; 46: 107-14.
4. Amagaya S, Hayagawa M, Ogihara Y, Fujiwara K. Effect of Syo-saiko-to and Dai-saiko-to on carbon tetrachloride-induced hepatic injury in rats. J Med Pharm Soc Wakan Yaku 1988; 5: 129-36. [Article in Japanese].
5. Amagaya S, Miyake A, Ogihara Y, Fujiwara K. Effect of Syo-saiko-to on liver regeneration in partially hepatectomized rats. J Med Pharm Soc Wakan Yaku 1988; 5: 137-45. [Article in Japanese].
6. Chen MH, Chen JC, Tsai CC etal. Sho-saiko-to prevents liver fibrosis induced by bile duct ligation in rats. Am J Chin Med 2004; 32: 195-207.
7. Haranaka K, Satomi N, Sakurai A etal. Antitumor activities and tumor necrosis factor producibility of traditional Chinese medicines and crude drugs. Cancer Immunol Immunother 1985; 20: 1-5.
8. Ito H, Shimura K. Effects of a blended Chinese medicine, Xiao-ChaiHu-Tang, on Lewis lung carcinoma growth and inhibition of lung metastasis, with special reference to macrophage activation. Jpn J Pharmacol 1986; 41: 307-14.
9. Sameshima H, Unno T, Hirakawa K etal. Acute and subacute toxicity of Sho-saiko-to. Pharmacometrics 1987; 33: 793-808. [Article in Japanese].
10. Minematsu S, Atkinson JE, Bolte HF etal. A subchronic (3-month) oral toxicity study of Tsumura Sho-saiko-to (TJ-9) in rats via oral gavage administration with a 4-weeks recovery period. Pharmacometrics 1992; 43: 19-42. [Article in Japanese].
11. Sasaki H. Kampo medicine products in japan. International Senior Forum of Traditional Chinese Medicine & Botanical Products. Speech Collection: 38-41, Hangzhou, China.
12. Ogihara Y. Sho-saiko-to. Bristol: Taylor & Francis, 2003; 42-45.
13. Nakata R, Tsukamoto I, Miyoshi M, Kojo S. Liver regeneration after carbon tetrachloride intoxication in the rat. Biochem Pharmacol 1985; 34: 586-8.
14. 4 hepatotoxicity: a novel dose-response. Toxicology 1997; 118: 181-93.
15. 4 autoprotection. Toxicol Pathol 1991; 4: 597-606.
16. 13C-galactose breath tests. Life Sci 1994; 54: 2093-8.
17. 4-hepatotocicity by phenobarbitone. J Pharm Pharmacol 1985; 37: 555-9.
18. Shibayama Y. Prevention of hepatotoxic responses to chemicals by glycyrrhizin in rats. Exp Mol Pathol 1989; 51: 48-55.
19. 4 treated rats. Yakugaku Zasshi 1991; 111: 531-7. [Article in Japanese].
20. Eybl V, Caisova D, Koutensky J, Waitzova D. Protective effect of Shosaiko-to (TJ-9) in experimental liver injury. Cesk Farm 1992; 41: 243-5. [Article in Czech].
21. Taira Z, Yabe K, Hamaguchi Y etal. Effects of Sho-saiko-to extract and its components, baicalin, baicalein, glycyrrhizin and glycyrrhetic acid, on pharmacokinetic behavior of salicylamide in carbon tetrachloride intoxicated rats. Food Chem Toxicol 2004; 42: 803-7.
22. D-galactosamine HCl. Acta Histochem Cytochem 1985; 18: 403-18.
23. D-galactosamine-induced hepatic injury of rats. Acta Histochem Cytochem 1988; 21: 439-53.
24. D-galactosamine in rats. Yakugaku Zasshi 1984; 104: 798-804. [Article in Japanese].
25. Kusunose M, Qiu B, Cui T etal. Effect of Sho-saiko-to extract on hepatic inflammation and fibrosis in dimethylnitrosamine induced liver injury rats. Biol Pharma Bull 2002; 25: 1417-21.
26. Mizoguchi Y, Shin T, Kawada N etal. The protective effects of Sho-saiko-to in an experimental, Immunologically-induced allergic hepatic cell injury. Jpn J Clin Immunol 1990; 13: 320-7. [Article in Japanese].
27. Mitsukawa H, Ikeda K. Effect of sho-saiko-to (xiao-chai-hu-tang) on hepatic injury induced by halothane in rats. Masui 1991; 40: 794-800. [Article in Japanese].
28. Miyamura M, Ono M, Kyotani S, Nishioka Y. Effects of Sho-saiko-to extract on fibrosis and regeneration of the liver in rats. J Pharm Pharmacol 1998; 50: 97-105.
29. Amagaya S, Hayakawa M, Ogihara Y etal. Treatment of chronic liver injury in mice by oral administration of Xiau-Chai-Hu-Tang. J Ethnopharmacol 1989; 25: 181-7.
30. Ji G, Wang YQ, Cao CL. Clinical study on treatment of alcoholic liver diseases by qinggan huoxue recipe. J Chin Integr Med 2004; 24: 13-16. [Article in Chinese].
31. Yaginuma T, Okamura T, Takeuchi T etal. Preventive effect of traditional herbal medicine, Shosaiko-to, on danazol-induced hepatic damage. Int J Gynaecol Obstet 1989; 29: 337-41.
32. Rojkind M, Perez-Tamayo R. Liver fibrosis. Int Rev Connect Tissue Res 1983; 10: 333-93.
33. Conn HO, Atterbury CE. Cirrhosis. In: Schiff L, Schiff ER, eds. Diseases of the Liver. Philadelphia: JB Lippincott, 1987; 725-864.
34. Bissel DM, Roll J. Connective tissue metabolism and hepatic fibrosis. In: Zakim D, Boyer TD, eds. Hepatology: A Textbook of Liver Disease, 2nd edn. Philadelphia, PA: WB Saunders, 1990; 424-44.
35. Li D, Friedman SL. Liver fibrogenesis and the role of hepatic stellate cell: new insights and prospects for therapy. J Gastroenterol Hepatol 1999; 14: 618-33.
36. Friedman SL. Cellular sources of collagen and regulation of collagen production in liver. Semin Liver Dis 1990; 10: 20-9.
37. Gressner AM, Bachem MG. Cellular sources of noncollagenous matrix proteins: role of fat-storing cells in fibrogenesis. Semin Liver Dis 1990; 10: 30-46.
38. Friedman SL. The cellular basis of hepatic fibrosis. Mechanisms and treatment strategies. N Engl J Med 1991; 328: 1828-35.
39. Lyons BL, Schwarz RI. Ascorbate stimulation of PAT cells causes an increase in transcription rates and a decrease in degradation rates of procollagen mRNA. Nucleic Acids Res 1984; 12: 2569-79.
40. Lee KS, Buck M, Houglum K, Chojkier M. Activation of hepatic stellate cells by TGF-α and collagen type II mediated by oxidative stress through c-myb expression. J Clin Invest 1995; 96: 2461-8.
41. Amagaya S, Hayagawa M, Ogihara Y, Fujiwara K. Effects of Syo-saiko-to and Dai-saiko-to on experimental hepatic fibrosis in rats. J Med Pharm Soc Wakan Yaku 1988; 5: 137-45.
42. Shimizu I, Ma YR, Mizobuchi Y etal. Effect of Sho-saiko-to, a Japanese herbal medicine, on hepatic fibrosis in rats. Hepatology 1999; 29: 149-60.
43. Ono M, Miyamura M, Kyotani S etal. Effects of Sho-saiko-to extract on liver fibrosis in relation to the change in hydroxyproline and retinoid levels of the liver in rats. J Pharm Pharmacol 1999; 51: 1079-84.
44. Kitade Y, Watanabe S, Masaki T etal. Inhibition of liver fibrosis in LEC rats by a carotenoid, lycopene, or a herbal medicine, Sho-saiko-to. Hepatol Res 2002; 22: 196-205.
45. Sakaida I, Matsumura Y, Akiyama S etal. Herbal medicine Sho-saiko-to (TJ-9) prevents liver fibrosis and enzyme-altered lesions in rat liver cirrhosis induced by a choline-deficient L-amino acid-defined diet. J Hepatol 1998; 28: 298-306.
46. Yoshiji H, Kuriyama S, Yoshii J etal. Extracellular matrix remodeling may predominate over hepatocyte injury in hepatocellular carcinoma development. Oncol Rep 2003; 10: 957-62.
47. Kayano K, Sakaida I, Uchida K, Okita K. Inhibitory effects of the herbal medicine Sho-saiko-to (TJ-9) on cell proliferation and procollagen gene expressions in cultured rat hepatic stellate cells. J Hepatol 1998; 29: 642-9.
48. Chen MH, Chen JC, Tsai CC etal. The role of TGF-β1 and cytokines in the modulation of liver fibrosis by Sho-saiko-to in rat's bile duct ligated model. J Ethnopharmacol 2005; 97: 7-13.
49. Sakaida I, Hironaka K, Kimura T etal. Herbal medicine Sho-saiko-to (TJ-9) increases expression matrix metalloproteinases (MMPs) with reduced expression of tissue inhibitor of metalloproteinases (TIMPs) in rat stellate cell. Life Sci 2004; 74: 2251-63.
50. Akriviadis EA, Llovet JM, Efremidis SC etal. Hepatocellular carcinoma. Br J Surg 1998; 85: 1319-31.
51. Johnson PJ, Williams R. Cirrhosis and the aetiology of hepatocellular carcinoma. J Hepatol 1987; 4: 140-7.
52. Macdonald GA. Pathogenesis of hepatocellular carcinoma. Clin Liver Dis 2001; 5 (1): 69-85.
53. Tarao K, Rino Y, Ohkawa S etal. Association between high serum alanine aminotransferase levels and more rapid development and higher rate of incidence of hepatocellular carcinoma in patients with hepatitis C virus-associated cirrhosis. Cancer 1999; 86: 589-95.
54. Tarao K, Takemiya S, Tamai S etal. Relationship between the recurrence of hepatocellular carcinoma (HCC) and serum alanine aminotransferase levels in hepatectomized patients with hepatitis C virus-associated cirrhosis and HCC. Cancer 1997; 79: 688-94.
55. Seeff LB. Natural history of hepatitis C. Hepatology 1997; 26: 21-8.
56. Benvegnu L, Alberti A. Risk factors and prevention of hepatocellular carcinoma in HCV infection. Dig Dis Sci 1996; 41: 49-55.
57. Theret N, Musso O, Turlin B etal. Increased extracellular matrix remodeling is associated with tumor progression in human hepatocellular carcinomas. Hepatology 2001; 34: 82-8.
58. 1 phase. Cancer Res 1994; 54: 448-54.
59. Chang JS, Wang KC, Liu HW etal. Sho-saiko-to (Xiao-Chai-Hu-Tang) and crude saikosaponins inhibit hepatitis B virus in a stable HBV-producing cell line. Am J Chin Med 2007; 35: 341-51.
60. Yamashiki M, Nishimura A, Nomoto M etal. Herbal medicine "Sho-saiko-to" induces tumor necrosis factor-alpha and granulocyte colony-stimulating factor in vitro in peripheral blood mononuclear cells of patients with hepatocellular carcinoma. J Gastroenterol Hepatol 1996; 11: 137-42.
61. Yamashiki M, Nishimura A, Suzuki H etal. Effects of the Japanese herbal medicine "Sho-saiko-to" (TJ-9) on in vitro interleukin-10 production by peripheral blood mononuclear cells of patients with chronic hepatitis C. Hepatology 1997; 25: 1390-7.
62. Zhu K, Fukasawa I, Furuno M. Inhibitory effects of herbal drugs on the growth of human ovarian cancer cell lines through the induction of apoptosis. Gynecol Oncol 2005; 97: 405-9.
63. Shiota G, Maeta Y, Mukoyama T etal. Effects of Sho-saiko-to on hepatocarcinogenesis and 8-hydroxy-2'-Deoxyguanosine formation. Hepatology 2002; 35: 1125-33.
64. Tatsuta M, Iishi H, Bada M etal. Inhibition by xiao-chai-hu-tang (TJ-9) of development of hepatic foci induced by N-nitrosomorpholine in Sprague-Dawley rats. Jpn J Cancer Res 1991; 82: 987-92.
65. Okita K, Kurokawa N, Yamasaki T etal. The use of Sho-saiko-to (TJ-9) for chemoprevention of chemical hepatocarcinogenesis in rats and discussion of its possible pharmacologic action. Transgenica 1995; 1: 39-44.
66. Sakamoto S, Mori T, Sawaki K etal. Effects of kampo (Japanese herbal) medicine "sho-saiko-to" on DNA-synthesizing enzyme activity in 1, 2 -dimethylhydrazine-induced colonic carcinomas in rats. Planta Med 1993; 59: 152-4.
67. Oka H, Yamamoto A, Kuroki T etal. Prospective study of chemoprevention of hepatocellular carcinoma with Sho-saiko-to (TJ-9). Cancer 1995; 76: 743-9.
68. Yamamoto S, Oka H, Mizoguchi Y, Kobayashi K. Controlled prospective trial to evaluate Shosaiko-to in preventing hepatocellular carcinoma in patients with cirrhosis of the liver. Jpn J Cancer Chemother 1989; 16: 1519-24. [Article in Japanese].
69. Hirayama C, Okumura M, Tanikawa K etal. A multicenter randomized controlled clinical trial of Sho-saiko-to in chronic active hepatitis. Gastroenterol Jpn 1989; 24: 715-9.
70. Gibo Y, Nakamura Y, Takahashi N etal. Clinical study of Sho-saiko-to therapy to the Japanese patients with chronic hepatitis type C (CH-C). Prog Med 1994; 7: 217-20.
71. Yamaoka Y, Kawakita T, Kaneko M, Nomoto K. A polysaccharide fraction of shosaiko-to active in augmenting natural killer activity by oral administration. Biol Pharm Bull 1995; 18: 846-9.
72. Kaneko M, Kawakita T, Tauchi Y etal. Augmentation of NK activity after oral administration of a traditional Chinese medicine, Xiao-Chai-Hu-Tang (Shosaiko-to). Immunopharmacol Immunotoxicol 1994; 16: 41-53.
73. Herberman RB, Nunn ME, Holden HT etal. Augmentation of natural cytotoxic reactivity of mouse lymphoid cells against syngeneic and allogeneic target cells. Int J Cancer 1977; 19: 555-64.
74. Herberman RB. Natural killer cells. Annu Rev Med 1986; 37: 347-52.
75. Ritz J, Schmidt RE, Michon J etal. Characterization of functional surface structures on human natural killer cells. Adv Immunol 1988; 42: 181-211.
76. Nencion L, Villa L, Boraschi D etal. Natural and antibody dependent cell-mediated activity against salmonella typhimurium by peripheral and intestinal lymphoid cells in mice. J Immunol 1983; 130: 903-7.
77. Herberman RB, Ortaldo JR, Bonnard GD. Augmentation by interferon of human natural and antiboby-dependent cell-mediated cytotoxicity. Nature 1979; 277: 221-31.
78. Djeu JY, Heinbaugh JA, Holden HT, Herberman RB. Augmentation of mouse natural killer cell activity by interferon and interferon inducers. J Immunol 1979; 122: 175-81.
79. Kawakita T, Nakai S, Kumazawa Y etal. Induction of interferon after administration of a traditional Chinese medicine, xiao-chai-hu-tang (Shosaiko-to). Int J Immunopharmacol 1990; 12: 515-21.
80. Yamashiki M, Nishimura A, Huang XX etal. Effects of Japanese herbal medicine "Sho-saiko-to" (TJ-9) on interleukin-12 production in patients with HCV-positive liver cirrhosis. Dev Immunol 1999; 7: 17-22.
81. Kojima K, Mizukami H, Tazawa T etal. Long-term administration of "Sho-saiko-to" increases cytochrome p-450 mRNA level in mouse liver. Biol Pharma Bull 1998; 21: 426-8.
82. Nose M, Tamura M, Ryu N etal. Sho-saiko-to and Saiko-keisi-to, the traditional Chinese and Japanese herbal medicines, altered hepatic drug-metabolizing enzymes in mice and rats when administered orally for a long time. J Pharm Pharmacol 2003; 55: 1419-26.
83. Hsu LM, Huang YS, Tsay SH etal. Acute hepatitis induced by Chinese hepatoprotective herb, Xiao-chai-hu-tang. J Clin Med Assoc 2006; 69: 86-8.
84. Daibo A, Yoshida Y, Kitazawa S etal. A case of pneumonitis and hepatic injury caused by herbal drug (Sho-saiko-to). Nihon Kyobu Shikkan Gakkai Zasshi 1992; 30: 1583-8. [Article in Japanese].
85. Sugiyama H, Nagai M, Kotajima F etal. A case of interstitial pneumonia with chronic hepatitis C following interferon-alpha and Sho-saiko-to therapy. Arerugi 1995; 44: 711-14. [Article in Japanese].
86. Sato A, Toyoshima M, Kondo A etal. Pneumonitis induced by the herbal medicine Sho-saiko-to in Japan. Nihon Kyobu Shikkan Gakkai Zasshi 1997; 35: 391-5. [Article in Japanese].
87. Kiguchi T, Kimura F, Niya K etal. Acute thrombocytopenic purpura after ingestion of Sho-saiko-to for hepatitis. Liver 2000; 20: 491.
88. Yoshida Y. A non-cardiogenic type of pulmonary edema after administration of Chinese herbal medicine (Shosaikoto) - A case report. Nihon Kokyuki Gakkai Zasshi 2003; 41: 300-3. [Article in Japanese].
89. Tomioka H, Hashimoto K, Ohnishi H etal. An autopsy case of interstitial pneumonia probably induced by Sho-saiko-to. Nihon Kokyuki Gakkai Zasshi 1999; 37: 1013-18. [Article in Japanese].
90. Tojima H, Yamazaki T, Tokudome T. Two cases of pneumonia caused by Sho-saiko-to. Nihon Kyobu Shikkan Gakkai Zasshi 1996; 34: 904-10. [Article in Japanese].
91. Sakamoto O, Ichikado K, Kohrogi H, Suga M. Clinical and CT characteristics of Chinese medicine-induced acute respiratory distress syndrome. Respirology 2003; 8: 344-50. [Article in Japanese].
92. Kawasaki A, Mizushima Y, Kunitani H etal. A useful diagnostic method for drug-induced pneumonitis: a case report. Am J Chin Med 1994; 22: 329-36.
93. Kobashi Y, Nakajima M, Niki Y, Matsushima T. A case of acute eosinophilic pneumonia due to Sho-saiko-to. Nihon Kyobu Shikkan Gakkai Zasshi 1997; 35: 1372-7. [Article in Japanese].
94. Takada N, Arai S, Kusuhara N etal. A case of Sho-saiko-to-induced pneumonitis, diagnosed by lymphocyte stimulation test using bronchoalveolar lavage fluid. Nihon Kyobu Shikkan Gakkai Zasshi 1993; 31: 1163-9. [Article in Japanese].
95. Wada T, Kubo M. Acute lymphoblastic leukemia complicated by type C hepatitis during treatment and further by acute interstitial pneumonia due to Sho-saiko-to in 7-years-old. Arerugi 1997; 46: 1148-55. [Article in Japanese].
96. Katou K, Mori K. Autoimmune hepatitis with drug-induced pneumonia due to Sho-saiko-to. Nihon Kyobu Shikkan Gakkai Zasshi 1999; 37: 641-6. [Article in Japanese].
97. Akira M, Ishikawa H, Yamamoto S. Drug-induced pneumonitis: thin-section CT findings in 60 patients. Radiology 2002; 224: 852-60.
98. Nakajima M, Manabe T, Mitekura H etal. Levels of serum KL-6 in a patient with drug-induced pneumonitis. Nihon Kyobu Shikkan Gakkai Zasshi 1997; 35: 813-17. [Article in Japanese].
99. Tsukiyama K, Tasaka Y, Nakajima M etal. A case of pneumonitis due to Sho-saiko-to. Nihon Kyobu Shikkan Gakkai Zasshi 1989; 27: 1556-61. [Article in Japanese].
100. Nishimori F, Yamazaki K, Yoshimura N etal. Pneumonitis induced by the drug ougon. Nihon Kokyuki Gakkai Zasshi 1999; 37: 396-400. [Article in Japanese].
101. Hatakeyama S, Tachibana A, Morita M, Suzuki K, Okano H. Five cases of pneumonitis induced by Sho-saiko-to. Nihon Kyobu Shikkan Gakkai Zasshi 1997; 35: 505-10. [Article in Japanese].
102. Nakagawa A, Yamaguchi T, Takao T, Amano H. Five cases of drug-induced pneumonitis due to Sho-saiko-to or interferon-alpha or both. Nihon Kyobu Shikkan Gakkai Zasshi 1995; 33: 1361-6. [Article in Japanese].
103. Ji FP, Li ZX, Deng H etal. Diagnosis and management of interstitial pneumonitis associated with interferon theraphy for chronic hepatitis C. World J Gastroenterol 2010; 16: 4394-9.
104. Murakami K, Okajima K, Sakata K, Takatsuki K. A possible mechanism of interstitial pneumonia during interferon therapy with Sho-saiko-to. Nihon Kyobu Shikkan Gakkai Zasshi 1995; 33: 389-94. [Article in Japanese].
105. Ohtake N, Suzuki R, Daikuhara H etal. Modulation of lung local immune responses by oral administration of a herbal medicine Sho-saiko-to. Int J Immunopharmacol 2000; 22: 419-30.
106. Matsuura K, Kawakita T, Nakai S etal. Role of B-lymphocytes in the immunopharmacological effects of traditional Chinese medicine, Xiao-chai-hu-tang (Sho-saiko-to). Int J Immunopharmacol 1993; 15: 237-43.